White Fibrous Clots: Embalmers’ Alarming Discoveries and Peer-Reviewed Science

How the Tennessee Funeral Directors Association Meeting and Cutting-Edge Studies Reveal a Disturbing Post-Vaccine Phenomenon

A chilling phenomenon has emerged since the COVID-19 vaccine rollout: embalmers worldwide are finding unusual white fibrous clots in deceased individuals. These observations took center stage at the Tennessee Funeral Directors Association meeting in June 2025, where embalmers reported widespread detection of these clots. Supported by peer-reviewed studies linking the SARS-CoV-2 spike protein to amyloidogenic fibrin aggregates, these findings point to a potential vaccine-related pathology that demands urgent attention. This blog post explores the scientific evidence and ties it to the embalmers’ revelations, shedding light on a critical public health issue.

The Tennessee Funeral Directors Association Meeting: A Wake-Up Call

In June 2025, the Tennessee Funeral Directors Association hosted a groundbreaking meeting where retired U.S. Air Force Major Thomas Haviland presented results from his "Worldwide Embalmer White Fibrous Clot Survey." Embalmers in attendance confirmed observing white fibrous clots in 17–27% of corpses since the COVID-19 vaccines were introduced in 2021. These rubbery, resistant clots, found in both veins and arteries, were described as unlike anything seen in decades of embalming practice.

These white fibrous clots started appearing in 2021, and I’ve never seen anything like them in my 20 years as an embalmer.” — Richard Hirschman, Embalmer

The meeting amplified the urgency of Haviland’s findings, which show that 83% of 301 embalmers surveyed in 2024 reported these clots, up from 73% in 2023. This consistency across global reports underscores the need to connect these observations to scientific research.

Peer-Reviewed Studies: The Spike Protein’s Role in Amyloidogenic Clots

Peer-reviewed studies provide a clear biological mechanism for the white fibrous clots, linking the SARS-CoV-2 spike protein—produced by mRNA vaccines—to amyloidogenic fibrin aggregates. These misfolded protein structures, resistant to breakdown, match the embalmers’ descriptions. Below are key scientific insights:

1. Spike Protein Triggers Amyloid Formation

A 2022 study in the Journal of the American Chemical Society identified seven amyloidogenic sequences in the SARS-CoV-2 spike protein. These peptides formed amyloid-like aggregates when exposed to neutrophil elastase, an enzyme common in inflammatory conditions. The resulting fibrils were resistant to plasmin, explaining the clots’ durability.

“The SARS-CoV-2 spike protein contains sequences that can form amyloid fibrils, potentially causing organ damage.” — Dr. Arturo Casadevall, Johns Hopkins University

2. Amyloid Microclots and Fibrin Pathology

Studies in Cardiovascular Diabetology (2021) and *Biochemical Journal* (2022) found that the spike protein induces fibrinogen to form amyloid microclots resistant to fibrinolysis. These clots, rich in fibrinogen and serum amyloid A, were detected in plasma and align with the embalmers’ findings of fibrous, protease-resistant structures.

“The SARS-CoV-2 spike protein alone can initiate amyloid microclot formation, no thrombin required.” — Dr. Douglas B. Kell, University of Liverpool

3. Altered Fibrinogen in Clot Formation

A 2022 *Journal of Thrombosis and Haemostasis* study revealed that fibrinogen in COVID-19 patients forms denser, stiffer clots due to increased sialic acid content. These clots resist breakdown, mirroring the white fibrous clots reported by embalmers.

4. Spike Protein and Coagulopathy

A 2025 *Frontiers* study showed that the spike protein, including mutations like D614G and N501Y, activates platelets and interacts with fibrinogen, promoting hyperfibrinolysis and elevated D-dimer levels. This coagulopathy mechanism supports the hypothesis that vaccine-induced spike protein could contribute to abnormal clotting.

Bridging Science and Embalmers’ Reports

The peer-reviewed studies align closely with the embalmers’ observations. The amyloidogenic fibrin aggregates described in the literature—resistant to breakdown and rich in misfolded proteins—match the white, rubbery clots found in corpses. Biochemical analyses by researchers like Greg Harrison and Dr. Kevin McCairn further confirm high phosphorus content (up to 4,900 ppm vs. normal 100–1,500 ppm) and abnormal fibrinogen ratios in these clots, suggesting spike protein-induced misfolding. The temporal link, with clots appearing after the 2021 vaccine rollout, strengthens the connection to mRNA vaccines.

The Tennessee meeting served as a critical platform for embalmers like Richard Hirschman to share these findings, supported by Haviland’s survey data. Their reports, combined with scientific evidence, paint a compelling picture of a post-vaccine pathology that cannot be ignored.

Why This Matters: A Public Health Imperative

The white fibrous clots represent a potential public health crisis, with embalmers and researchers sounding the alarm. The CDC and FDA have yet to respond to Haviland’s annual submissions, as noted on X, leaving critical questions unanswered. The studies suggest that vaccine-induced spike protein could drive amyloidogenic clotting, a risk that demands immediate investigation to protect public safety.

“Embalmers and independent researchers are uncovering a post-vaccine pathology that institutions must address now.” — Thomas Haviland, USAF Ret. Major

A Call to Action

The evidence from peer-reviewed studies and the Tennessee Funeral Directors Association meeting demands swift action:

1. Fund Research: Support studies to analyze clots using advanced techniques like Thioflavin T fluorescence and electron microscopy.

2. Conduct Autopsies: Perform systematic autopsies to correlate clot presence with vaccination status and medical history.

3. Engage Regulators: The CDC and FDA must investigate embalmers’ data and assess amyloidogenic risks from vaccine-induced spike protein.

4. Raise Awareness: Share findings to ensure the public and policymakers prioritize this issue.

Conclusion

The white fibrous clots reported by embalmers, brought to light at the Tennessee Funeral Directors Association meeting, are backed by robust peer-reviewed studies linking the SARS-CoV-2 spike protein to amyloidogenic fibrin aggregates. From the Journal of the American Chemical Society to Frontiers, the science confirms that the spike protein can drive pathological clotting, matching the embalmers’ descriptions of rubbery, resistant clots. As researchers like Dr. Kevin McCairn and embalmers like Richard Hirschman push for answers, the public health community must act to investigate this phenomenon. The time for silence is over—let’s uncover the truth behind these clots and ensure accountability.